Ken Griffin
CERE

Ken Griffin’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Ken Griffin’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-81,100
Closed -$3.32M – 15634
2024
Q2 		$3.32M Buy
81,100
+22,700
+39% +$945K ﹤0.01% 4403
2024
Q1 		$2.47M Sell
58,400
-25,000
-30% -$1.05M ﹤0.01% 5113
2023
Q4 		$3.54M Buy
83,400
+60,100
+258% +$1.73M ﹤0.01% 4360
2023
Q3 		$509K Sell
23,300
-25,400
-52% -$636K ﹤0.01% 8043
2023
Q2 		$1.55M Buy
48,700
+24,800
+104% +$761K ﹤0.01% 5630
2023
Q1 		$583K Sell
23,900
-12,500
-34% -$367K ﹤0.01% 8005
2022
Q4 		$1.15M Buy
36,400
+3,900
+12% +$110K ﹤0.01% 6547
2022
Q3 		$918K Buy
32,500
+11,000
+51% +$328K ﹤0.01% 7183
2022
Q2 		$568K Buy
21,500
+600
+3% +$17K ﹤0.01% 8361
2022
Q1 		$732K Sell
20,900
-36,700
-64% -$1.07M ﹤0.01% 8460
2021
Q4 		$1.87M Sell
57,600
-31,100
-35% -$1.1M ﹤0.01% 6414
2021
Q3 		$2.62M Sell
88,700
-119,200
-57% -$3.35M ﹤0.01% 5697
2021
Q2 		$5.33M Buy
+207,900
New +$2.98M ﹤0.01% 4298

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Ken Griffin's CERE Position: Q3 2024 in Review

Ken Griffin sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 955,818 shares — an estimated $39.1M sold.

Ken Griffin first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $39.1M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Ken Griffin reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Ken Griffin sold 955,818 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $39.1M.
  • Ken Griffin first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • Ken Griffin's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $39.1M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.